A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: Docetaxel|DRUG: Paclitaxel|DRUG: Eribulin
Sponsor: Japan Breast Cancer Research Group
Collaborators: Eisai Co., Ltd.